Cardiogen

How does Cardiogen work?

Cardiogen is a Khavinson short peptide studied as an organ-targeted bioregulator in cardiac tissue. Its proposed actions center on cardiomyocyte proliferation, reduced myocardial apoptosis, and a shift of cardiac fibroblasts away from a fibrotic phenotype, with gene-expression modulation as the underlying mechanism. The points below are hypotheses drawn from preclinical tissue-culture and rodent models, not established human mechanisms.

1. Cardiomyocyte Proliferation [1]. In myocardial tissue culture from both young and old rats, Cardiogen stimulated cell proliferation (Chalisova et al. 2009).
2. Reduced Myocardial Apoptosis [1]. In the same cultured cardiac tissue, immunohistochemistry showed decreased p53 expression, suggesting suppression of apoptosis (Chalisova et al. 2009).
3. Anti-Fibrotic Fibroblast Shift (hypothesized). Cardiogen is proposed to shift cardiac fibroblasts toward a less-fibrotic phenotype — less scar formation and collagen overdeposition. This remains a hypothesis from preclinical work.
4. Direct DNA / Gene-Expression Modulation [3]. As a Khavinson short peptide, AEDR is hypothesized to penetrate cells and modulate gene expression through site-specific binding to DNA and modulation of endonuclease activity (Khavinson et al. 2011).

What is Cardiogen researched for?

Cardiogen's research base is entirely preclinical — rodent and in-vitro tissue culture — and comes largely from the Khavinson research lineage, with much of it in Russian-language journals. There are no human randomized controlled trials. The cardioprotection claims rest substantially on patent material rather than peer-reviewed clinical data; read the findings below with that in mind.

1. Myocardial Tissue-Culture Proliferation [1]. Cardiogen stimulated proliferation in myocardial tissue culture from young and old rats; immunohistochemistry showed decreased p53, suggesting apoptosis inhibition (Chalisova et al. 2009). Russian-language; preclinical.
2. Cardioprotection in Rodent Models (US patent). US Patent 7,662,789 — Peptide substance restoring myocardium function (Ala-Glu-Asp-Arg) — describes cardioprotective activity across rodent models, including coronary-artery-ligation infarction, ischemia-reperfusion, adrenaline dystrophy, and arrhythmia. As patent material, this is not peer-reviewed clinical evidence.
3. Tumor-Modifying Effect [2]. A study reported a tumor-modifying effect of Cardiogen on M-1 sarcoma in senescent rats (Levdik & Knyazkin 2009).
4. Molecular Mechanism — Peptide–DNA Binding [3]. Site-specific binding of short peptides (including AEDR) with DNA, modulating eukaryotic endonuclease activity, provides a proposed molecular basis for the gene-expression effects (Khavinson et al. 2011).
5. Systematic-Review Context [4]. A 2021 open-access systematic review of peptide regulation of gene expression covers Cardiogen among the bioregulators surveyed (Khavinson et al. 2021).

How is Cardiogen dosed?

There is no validated or FDA-approved dose for Cardiogen. It is handled as a research-use-only lyophilized powder, and the published work is preclinical animal and in-vitro tissue-culture research rather than human dosing studies.

Because no controlled human dosing studies exist, there is no established human dose, and any figure circulated for injectable Cardiogen is extrapolated rather than validated. Researchers handling the lyophilized powder reconstitute it with bacteriostatic or sterile water (see storage below); any volume chosen is a generic handling convenience, not a dosing recommendation. Prof. Peptide deliberately does not publish an injectable mg or mg/kg schedule — none has been validated in controlled research.

What are the side effects of Cardiogen?

Cardiogen's human safety profile is not characterized. The available evidence is entirely preclinical (rodent and in-vitro tissue culture), so there is no controlled human adverse-event data to summarize. This is a Research Use Only compound and is not intended for human consumption; nothing here should be read as human-use guidance. The honest summary is that human tolerability, interactions, and long-term safety are simply unknown.

How should Cardiogen be stored?

1. Lyophilized (powder) form: store cold and desiccated, protected from light. Freeze at -20°C for long-term storage; 2–8°C is acceptable short-term.
2. Reconstitute with bacteriostatic or sterile water for injection. Add the water slowly down the inside wall of the vial and swirl gently — do not shake.
3. Reconstituted solution: refrigerate at 2–8°C and keep protected from light.
4. Protect from light at all times; store in original packaging.
5. Discard if the solution is cloudy, discolored, or contains particles.

What are the limitations of Cardiogen research?

This is the most important section to read carefully. The Cardiogen evidence base is entirely preclinical — rodent and in-vitro tissue culture — and there are no human clinical trials.

Where to source Cardiogen

Cardiogen is not approved for human use and is sold by specialty research peptide vendors for laboratory use only. Quality varies across vendors — verify a Certificate of Analysis before purchase.

Cardiogen FAQ

References

1. Chalisova NI, et al. Effect of the Cardiogen peptide on proliferation in myocardial tissue culture from young and old rats. Adv Gerontol. 2009;22(3):409-13. PMID 20210190. https://pubmed.ncbi.nlm.nih.gov/20210190/
2. Levdik NV, Knyazkin IV. Tumor-modifying effect of the Cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med. 2009;148(3):433-6. PMID 20396706. https://pubmed.ncbi.nlm.nih.gov/20396706/
3. Khavinson VKh, Fedoreyeva LI, Vanyushin BF. Site-specific binding of short peptides with DNA modulates endonuclease activity. Bull Exp Biol Med. 2011;151(1):66-70. PMID 22442805. https://pubmed.ncbi.nlm.nih.gov/22442805/
4. Khavinson VK, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID 34834147. (Open Access) https://pubmed.ncbi.nlm.nih.gov/34834147/
5. US Patent 7,662,789. Peptide substance restoring myocardium function (Ala-Glu-Asp-Arg). Cardioprotective activity in rodent models (coronary-artery-ligation infarction, ischemia-reperfusion, adrenaline dystrophy, arrhythmia). Patent document; no PubMed/DOI.

Published Studies